Nurix Therapeutics Files 8-K
Ticker: NRIX · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1549595
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: NRIX
TL;DR
Nurix filed an 8-K, likely standard updates, no major news here.
AI Summary
Nurix Therapeutics, Inc. filed an 8-K on March 11, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text, but serves as a notification of these items.
Why It Matters
This filing indicates that Nurix Therapeutics is providing updates on its corporate activities and financial status to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for other events and financial statements, with no specific material events detailed in the provided text.
Key Players & Entities
- Nurix Therapeutics, Inc. (company) — Registrant
- March 11, 2024 (date) — Date of Report
- 1700 Owens Street, Suite 205 (location) — Principal Executive Offices Address
- San Francisco, California (location) — Principal Executive Offices City and State
- 94158 (location) — Principal Executive Offices Zip Code
- (415) 660-5320 (phone_number) — Registrant's Telephone Number
FAQ
What specific 'Other Events' are being reported by Nurix Therapeutics in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' being reported, only that this item is being addressed.
What financial statements or exhibits are included with this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific content of these documents is not detailed in the provided text.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported in this 8-K filing is March 11, 2024.
What is Nurix Therapeutics, Inc.'s IRS Employer Identification Number?
Nurix Therapeutics, Inc.'s IRS Employer Identification Number is 27-0838048.
What is the Commission File Number for Nurix Therapeutics, Inc.?
The Commission File Number for Nurix Therapeutics, Inc. is 001-39398.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-03-11 07:02:50
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share NRIX Nasdaq Global
Filing Documents
- nrix-20240311.htm (8-K) — 28KB
- nrix-20240311ex9918xk2127c.htm (EX-99.1) — 12KB
- 0001549595-24-000038.txt ( ) — 169KB
- nrix-20240311.xsd (EX-101.SCH) — 2KB
- nrix-20240311_lab.xml (EX-101.LAB) — 22KB
- nrix-20240311_pre.xml (EX-101.PRE) — 13KB
- nrix-20240311_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On March 11, 2024, Nurix Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has lifted the partial clinical hold on the Company's Phase 1 clinical trial evaluating NX-2127 for the treatment of various B-cell malignancies. The partial clinical hold was announced by the Company on November 1, 2023, following the Company's communication to the FDA of its intention to transition to an improved manufacturing process. A copy of the Company's press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed herewith and this list is intended to constitute the exhibit index: Exhibit No. Exhibit Title or Description 99.1 Nurix Therapeutics, Inc. press release dated March 11, 202 4 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NURIX THERAPEUTICS, INC. Date: March 11, 2024 By: /s/ Christine Ring Christine Ring, Ph.D., J.D. Chief Legal Officer and Chief Compliance Officer 3